Key result
Dexrazoxane significantly reduced doxorubicin-induced QTc prolongation in isolated guinea-pig hearts and prevented doxorubicin-induced inhibition of the slow delayed rectifier potassium current (IKs).
Why the study?
Does dexrazoxane prevent doxorubicin-induced QT prolongation and ion channel inhibition in preclinical models?
Population
Guinea-pig isolated Langendorff-perfused hearts and human embryonic kidney 293 cells stably expressing hERG…
Comparison
Doxorubicin with or without dexrazoxane perfused… vs Time-matched vehicle perfusion or moxifloxacin…
Design
Preclinical
Follow-up
45 minutes
Authors
Loading...
Does not support clinical use for QTc protection; leaves open whether IKs preservation reduces arrhythmias in patients.
Does dexrazoxane prevent doxorubicin-induced QT prolongation and ion channel inhibition in preclinical models?
Absolute Event Rate: 266% vs 283.1%
p-value: p=<0.01
Dexrazoxane prevents acute doxorubicin-induced QT prolongation by protecting against IKs blockade, demonstrating the importance of IKs screening in preclinical proarrhythmia testing.
Ducroq et al. (2009) studied Doxorubicin-induced QT prolongation (n=48). Dexrazoxane vs. Doxorubicin alone (30 µM) was evaluated on QTc interval (Fredericia) at 45 minutes (ms) (p=<0.01). Dexrazoxane significantly reduced doxorubicin-induced QTc prolongation in isolated guinea-pig hearts and prevented doxorubicin-induced inhibition of the slow delayed rectifier potassium current (IKs).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: